Abstract
The optimal timing for initiating extracorporeal membrane oxygenation (ECMO) after starting mechanical ventilation has yet to be clarified. We report herein the cases of two patients with coronavirus disease 2019 (COVID-19) acute respiratory distress syndrome (ARDS) who were successfully managed with an early ECMO induction strategy. Case 1 involved a 64-year-old man and Case 2 a 49-year-old man, both requiring intubation for severe respiratory distress. ECMO was initiated within 4 hours of intubation for both patients. This strategy may have minimized the risk of ventilator-induced lung injury (VILI) and contributed to favorable outcomes, with both patients discharged successfully.
Introduction
For patients with severe COVID-19-induced Acute Respiratory Distress Syndrome (ARDS), mechanical ventilation is the standard of care. However, when lungs are severely inflamed, the high pressures required to maintain oxygenation can cause further trauma, known as Ventilator-Induced Lung Injury (VILI). Extracorporeal Membrane Oxygenation (ECMO) acts as an external lung, allowing for "lung rest" by bypassing the need for aggressive mechanical ventilation.
The critical question in critical care is the timing of ECMO initiation. Current guidelines from the Extracorporeal Life Support Organization (ELSO) often suggest considering ECMO within six days of intubation if oxygenation remains poor. However, waiting days while the lungs are subjected to high-pressure ventilation might result in irreversible damage. This paper investigates whether an "early induction" strategy—initiating venovenous (VV) ECMO within hours of intubation—improves clinical outcomes.
Methods and Case Presentations
This study details a clinical case series of two male patients treated at Hirosaki University Hospital in Japan. Both patients presented with severe respiratory distress and confirmed COVID-19.
The clinical team employed a proactive "early induction" strategy:
- Intubation & Assessment: Patients were intubated when respiratory distress became severe.
- Rapid Escalation: Instead of waiting days to observe the effects of high-pressure ventilation, the team assessed oxygenation (P/F ratio) and lung compliance within the first few hours.
- VV-ECMO Initiation: VV-ECMO was started within 3–4 hours of intubation for both cases.
- Lung-Protective Strategy: Once on ECMO, ventilator settings were immediately dialed back to "lung rest" levels (low tidal volumes and limited inspiratory pressure) to allow the biological lungs to heal without mechanical stress.
Results
Both patients responded favorably to the early intervention. Case 1 (64M) was initiated on ECMO 4 hours post-intubation and remained on the circuit for 12 days. Case 2 (49M) was initiated just 3 hours post-intubation and was successfully weaned from ECMO in only 6 days.
As shown in the clinical data, both patients had significant respiratory compromise (P/F ratios of 127 and 93, respectively) and moderate RESP scores. Despite the severity, the early "lung rest" facilitated rapid recovery. Case 1 was discharged on hospital day 36, and Case 2 was discharged on day 21. Both patients avoided the typical complications associated with long-term high-pressure ventilation.
Discussion
The authors argue that the "ultra-early" window—initiating ECMO within the first few hours of intubation—prevents a "vicious cycle" where poor lung function requires higher ventilator pressures, which in turn causes more lung damage. By protecting the lungs from the onset, the duration of ECMO was relatively short compared to average severe COVID-19 cases in international registries.
While Respiratory ECMO Survival Prediction (RESP) scores are valuable for predicting survival, these cases suggest that the timing of the intervention may be just as critical as the patient's baseline risk. Early initiation allows for immediate implementation of ultra-protective ventilation, potentially facilitating faster biological recovery.
Limitations and Future Work
The primary limitation of this study is the small sample size (n=2). While these results are promising, they cannot definitively establish early initiation as the superior standard for all patients. Additionally, ECMO is a resource-intensive therapy requiring specialized teams. Future research, ideally randomized controlled trials, is needed to compare "ultra-early" initiation against the standard "wait and see" approach to determine if the benefits of early lung protection outweigh the risks and resource costs of early cannulation.
Summary updated